Cardiff Oncology, Inc. - 8-K Filing
Cardiff Oncology reports Q3 2026 net loss of $30.4 million and announces onvansertib Phase 2 clinical progress with median PFS not yet reached in the 30 mg arm. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CRDF